AstraZeneca Announces $100 Million R&D Investment in China
New Innovation Centre to Focus Initially on Oncology Research
AstraZeneca intents to invest $100 million in R&D in China over the next three years, focusing on the benefit and value of innovative medicines for Chinese patients. The prime focus of this programme will be the establishment of the AstraZeneca Innovation Centre China. The company has initiated a comprehensive search for an appropriate location for the Innovation Centre, which will be operational by the end of 2009. The Centre will focus on translational science by developing knowledge about Chinese patients, biomarkers and genetics. The initial therapeutic area for the Innovation Centre will be cancer.
In addition, AstraZeneca will expand its clinical research capabilities and is looking to increase the number of scientific collaborations with local Chinese organisations. AstraZeneca has recently signed a deal worth $14 million with Wuxi Pharmatech for Compound Collection Synthesis and has an existing collaboration with Shanghai Jiao Tong University on the genetics of schizophrenia.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Last viewed contents
Surprising discovery could lead to better batteries
Dow acquires Rohm and Haas, creating world's leading specialty chemicals and advanced materials company - $18.8 billion transaction marks pivotal point in Dow's transformation
Small change for a big improvement – halogen bonds and drug discovery
Texere Publishing Ltd. - Knutsford, United Kingdom
Univar Solutions B.V. - Rotterdam, Netherlands
Blockbusters Going off Patent - Opportunities for Generics - Growing Demand for Inexpensive, Effective Drugs and Continuing Patent Expiries ProvideGrowth Prospects for the European Generics Market
Rohm and Haas announces price increase for methacrylate monomers
Making plastic recycling more efficient - Klaus Feichtinger and Manfred Hackl named European Inventor Award 2019 finalists
Watching the charge move in photoexcited molecules - Research opens up the possibility to map the charge flowing inside the molecular landscape
LANXESS expands capacity of microbial active ingredient Preventol CMK by 50 percent - Long-term trend towards more disinfection
